nodes	percent_of_prediction	percent_of_DWPC	metapath
Naloxone—CYP3A4—bone cancer	0.639	1	CbGaD
Naloxone—SLCO1A2—Methotrexate—bone cancer	0.0478	0.377	CbGbCtD
Naloxone—ALB—Methotrexate—bone cancer	0.0247	0.195	CbGbCtD
Naloxone—ABCB1—Cisplatin—bone cancer	0.0199	0.157	CbGbCtD
Naloxone—ABCB1—Doxorubicin—bone cancer	0.0133	0.105	CbGbCtD
Naloxone—ABCB1—Methotrexate—bone cancer	0.0129	0.102	CbGbCtD
Naloxone—CYP3A4—Doxorubicin—bone cancer	0.00798	0.0631	CbGbCtD
Naloxone—Oxymorphone—CYP3A4—bone cancer	0.00108	0.211	CrCbGaD
Naloxone—Hydrocodone—CYP3A4—bone cancer	0.000942	0.184	CrCbGaD
Naloxone—Oxycodone—CYP3A4—bone cancer	0.000859	0.168	CrCbGaD
Naloxone—Buprenorphine—CYP3A4—bone cancer	0.000792	0.155	CrCbGaD
Naloxone—Hydromorphone—CYP3A4—bone cancer	0.00078	0.153	CrCbGaD
Naloxone—Morphine—CYP3A4—bone cancer	0.000663	0.13	CrCbGaD
Naloxone—Rhinorrhoea—Cisplatin—bone cancer	0.000434	0.0365	CcSEcCtD
Naloxone—Pain—Carboplatin—bone cancer	0.000366	0.0307	CcSEcCtD
Naloxone—Body temperature increased—Carboplatin—bone cancer	0.000338	0.0284	CcSEcCtD
Naloxone—Encephalopathy—Methotrexate—bone cancer	0.0003	0.0253	CcSEcCtD
Naloxone—Irritability—Cisplatin—bone cancer	0.000243	0.0205	CcSEcCtD
Naloxone—Nasopharyngitis—Cisplatin—bone cancer	0.000228	0.0192	CcSEcCtD
Naloxone—Ventricular tachycardia—Epirubicin—bone cancer	0.00018	0.0152	CcSEcCtD
Naloxone—Injection site reaction—Epirubicin—bone cancer	0.000179	0.0151	CcSEcCtD
Naloxone—Coma—Methotrexate—bone cancer	0.000176	0.0148	CcSEcCtD
Naloxone—Pulmonary oedema—Methotrexate—bone cancer	0.000172	0.0144	CcSEcCtD
Naloxone—Ventricular tachycardia—Doxorubicin—bone cancer	0.000167	0.014	CcSEcCtD
Naloxone—Injection site reaction—Doxorubicin—bone cancer	0.000166	0.014	CcSEcCtD
Naloxone—Coma—Epirubicin—bone cancer	0.000165	0.0139	CcSEcCtD
Naloxone—Flushing—Cisplatin—bone cancer	0.000164	0.0138	CcSEcCtD
Naloxone—Cardiac disorder—Cisplatin—bone cancer	0.000164	0.0138	CcSEcCtD
Naloxone—Pulmonary oedema—Epirubicin—bone cancer	0.000161	0.0135	CcSEcCtD
Naloxone—Mediastinal disorder—Cisplatin—bone cancer	0.000159	0.0134	CcSEcCtD
Naloxone—Coma—Doxorubicin—bone cancer	0.000153	0.0128	CcSEcCtD
Naloxone—Pulmonary oedema—Doxorubicin—bone cancer	0.000149	0.0125	CcSEcCtD
Naloxone—Tremor—Cisplatin—bone cancer	0.000144	0.0121	CcSEcCtD
Naloxone—Hot flush—Epirubicin—bone cancer	0.00014	0.0118	CcSEcCtD
Naloxone—Menopausal symptoms—Epirubicin—bone cancer	0.000139	0.0117	CcSEcCtD
Naloxone—ALB—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.000136	0.000627	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—FUS—bone cancer	0.000136	0.000624	CbGpPWpGaD
Naloxone—ESR1—AP-1 transcription factor network—TP53—bone cancer	0.000135	0.000622	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—GRM4—bone cancer	0.000135	0.00062	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—RGS1—bone cancer	0.000135	0.00062	CbGpPWpGaD
Naloxone—CREB1—Circadian rythm related genes—JUN—bone cancer	0.000135	0.000619	CbGpPWpGaD
Naloxone—CREB1—Downstream signaling of activated FGFR—EGFR—bone cancer	0.000135	0.000618	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000134	0.000614	CbGpPWpGaD
Naloxone—Irritability—Methotrexate—bone cancer	0.000134	0.0112	CcSEcCtD
Naloxone—Convulsion—Cisplatin—bone cancer	0.000133	0.0112	CcSEcCtD
Naloxone—CREB1—Integrated Breast Cancer Pathway—EGFR—bone cancer	0.000133	0.000612	CbGpPWpGaD
Naloxone—CREB1—Signaling by ERBB4—EGFR—bone cancer	0.000132	0.000609	CbGpPWpGaD
Naloxone—TLR4—Innate Immune System—EGFR—bone cancer	0.00013	0.0006	CbGpPWpGaD
Naloxone—CYP2C8—Biological oxidations—GSTP1—bone cancer	0.00013	0.000597	CbGpPWpGaD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.00013	0.0109	CcSEcCtD
Naloxone—Hot flush—Doxorubicin—bone cancer	0.00013	0.0109	CcSEcCtD
Naloxone—OPRM1—GPCR downstream signaling—GRM1—bone cancer	0.000129	0.000592	CbGpPWpGaD
Naloxone—Menopausal symptoms—Doxorubicin—bone cancer	0.000128	0.0108	CcSEcCtD
Naloxone—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	0.000128	0.000589	CbGpPWpGaD
Naloxone—ESR1—Integrated Breast Cancer Pathway—MDM2—bone cancer	0.000128	0.000586	CbGpPWpGaD
Naloxone—ESR1—Signaling by ERBB4—MDM2—bone cancer	0.000127	0.000583	CbGpPWpGaD
Naloxone—CREB1—Downstream signal transduction—EGFR—bone cancer	0.000126	0.000581	CbGpPWpGaD
Naloxone—CREB1—Signaling by FGFR—EGFR—bone cancer	0.000126	0.000578	CbGpPWpGaD
Naloxone—CREB1—EGF/EGFR Signaling Pathway—EGFR—bone cancer	0.000126	0.000578	CbGpPWpGaD
Naloxone—CREB1—Signaling by ERBB2—EGFR—bone cancer	0.000125	0.000576	CbGpPWpGaD
Naloxone—CREB1—DAP12 signaling—EGFR—bone cancer	0.000125	0.000573	CbGpPWpGaD
Naloxone—Cardiac arrest—Epirubicin—bone cancer	0.000125	0.0105	CcSEcCtD
Naloxone—ALB—Platelet activation, signaling and aggregation—IL3—bone cancer	0.000124	0.000568	CbGpPWpGaD
Naloxone—Nervous system disorder—Cisplatin—bone cancer	0.000123	0.0103	CcSEcCtD
Naloxone—CREB1—Downstream signaling events of B Cell Receptor (BCR)—EGFR—bone cancer	0.000123	0.000564	CbGpPWpGaD
Naloxone—Tachycardia—Cisplatin—bone cancer	0.000122	0.0103	CcSEcCtD
Naloxone—Skin disorder—Cisplatin—bone cancer	0.000122	0.0102	CcSEcCtD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000122	0.000559	CbGpPWpGaD
Naloxone—Hyperhidrosis—Cisplatin—bone cancer	0.000121	0.0102	CcSEcCtD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.00012	0.000552	CbGpPWpGaD
Naloxone—CREB1—Neuronal System—MDM2—bone cancer	0.000119	0.000548	CbGpPWpGaD
Naloxone—CREB1—Axon guidance—MMP2—bone cancer	0.000119	0.000547	CbGpPWpGaD
Naloxone—CREB1—Signaling by FGFR in disease—EGFR—bone cancer	0.000117	0.000539	CbGpPWpGaD
Naloxone—CREB1—DAP12 interactions—EGFR—bone cancer	0.000117	0.000539	CbGpPWpGaD
Naloxone—CREB1—Fc epsilon receptor (FCERI) signaling—EGFR—bone cancer	0.000117	0.000539	CbGpPWpGaD
Naloxone—Nasopharyngitis—Epirubicin—bone cancer	0.000117	0.00985	CcSEcCtD
Naloxone—OPRM1—Signaling by GPCR—GRM1—bone cancer	0.000117	0.000537	CbGpPWpGaD
Naloxone—CREB1—Signaling by NGF—MDM2—bone cancer	0.000117	0.000537	CbGpPWpGaD
Naloxone—CREB1—Signaling by EGFR—EGFR—bone cancer	0.000116	0.000534	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000116	0.000532	CbGpPWpGaD
Naloxone—Cardiac arrest—Doxorubicin—bone cancer	0.000115	0.00969	CcSEcCtD
Naloxone—CREB1—Signaling by EGFR in Cancer—EGFR—bone cancer	0.000115	0.000529	CbGpPWpGaD
Naloxone—CREB1—Signaling by PDGF—EGFR—bone cancer	0.000115	0.000527	CbGpPWpGaD
Naloxone—ALB—Selenium Micronutrient Network—PTGS2—bone cancer	0.000114	0.000526	CbGpPWpGaD
Naloxone—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	0.000114	0.000523	CbGpPWpGaD
Naloxone—Paraesthesia—Cisplatin—bone cancer	0.000113	0.00947	CcSEcCtD
Naloxone—OPRD1—GPCR downstream signaling—GNA11—bone cancer	0.000112	0.000514	CbGpPWpGaD
Naloxone—Dyspnoea—Cisplatin—bone cancer	0.000112	0.0094	CcSEcCtD
Naloxone—CREB1—Integrated Breast Cancer Pathway—TP53—bone cancer	0.000112	0.000514	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—SMO—bone cancer	0.000111	0.000512	CbGpPWpGaD
Naloxone—TLR4—Immune System—MDM2—bone cancer	0.000111	0.000511	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—SMO—bone cancer	0.000111	0.000511	CbGpPWpGaD
Naloxone—ESR1—Integrated Breast Cancer Pathway—JUN—bone cancer	0.000111	0.00051	CbGpPWpGaD
Naloxone—CREB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	0.00011	0.000507	CbGpPWpGaD
Naloxone—CREB1—B Cell Activation—EGFR—bone cancer	0.000108	0.000499	CbGpPWpGaD
Naloxone—Nasopharyngitis—Doxorubicin—bone cancer	0.000108	0.00912	CcSEcCtD
Naloxone—Gastrointestinal disorder—Cisplatin—bone cancer	0.000108	0.0091	CcSEcCtD
Naloxone—CREB1—Signaling Pathways—GRM4—bone cancer	0.000108	0.000496	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—RGS1—bone cancer	0.000108	0.000496	CbGpPWpGaD
Naloxone—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	0.000108	0.000495	CbGpPWpGaD
Naloxone—Depression—Methotrexate—bone cancer	0.000108	0.00905	CcSEcCtD
Naloxone—OPRD1—Signaling Pathways—RGS1—bone cancer	0.000107	0.000494	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—GRM4—bone cancer	0.000107	0.000494	CbGpPWpGaD
Naloxone—Pain—Cisplatin—bone cancer	0.000107	0.00902	CcSEcCtD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.000106	0.000486	CbGpPWpGaD
Naloxone—CREB1—NGF signalling via TRKA from the plasma membrane—EGFR—bone cancer	0.000104	0.000477	CbGpPWpGaD
Naloxone—Sweating—Methotrexate—bone cancer	0.000103	0.0087	CcSEcCtD
Naloxone—CREB1—Signaling by GPCR—GNA11—bone cancer	0.000102	0.000469	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.000102	0.000468	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—CDK4—bone cancer	0.000102	0.000468	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—MET—bone cancer	0.000102	0.000468	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000102	0.000468	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—GNA11—bone cancer	0.000102	0.000467	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—IL3—bone cancer	0.000101	0.000466	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000101	0.000466	CbGpPWpGaD
Naloxone—CREB1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.0001	0.000461	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—TUBB2A—bone cancer	9.99e-05	0.000459	CbGpPWpGaD
Naloxone—CREB1—Disease—ENO2—bone cancer	9.92e-05	0.000456	CbGpPWpGaD
Naloxone—Body temperature increased—Cisplatin—bone cancer	9.91e-05	0.00834	CcSEcCtD
Naloxone—OPRK1—GPCR downstream signaling—GNA11—bone cancer	9.81e-05	0.000451	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—SMO—bone cancer	9.74e-05	0.000448	CbGpPWpGaD
Naloxone—Sweating—Epirubicin—bone cancer	9.68e-05	0.00814	CcSEcCtD
Naloxone—TLR4—Immune System—JUN—bone cancer	9.66e-05	0.000444	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—GRM4—bone cancer	9.42e-05	0.000433	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—RGS1—bone cancer	9.42e-05	0.000433	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—NR1I2—bone cancer	9.41e-05	0.000433	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—GRM1—bone cancer	9.35e-05	0.00043	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—GRM1—bone cancer	9.32e-05	0.000428	CbGpPWpGaD
Naloxone—CREB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	9.26e-05	0.000426	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—IL3—bone cancer	9.24e-05	0.000425	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—IL3—bone cancer	9.21e-05	0.000424	CbGpPWpGaD
Naloxone—CREB1—Disease—DHFR—bone cancer	9.2e-05	0.000423	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	9.19e-05	0.000422	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—NDUFA12—bone cancer	9.1e-05	0.000419	CbGpPWpGaD
Naloxone—ALB—Metabolism—NDUFA12—bone cancer	9.05e-05	0.000416	CbGpPWpGaD
Naloxone—Asthenia—Cisplatin—bone cancer	9e-05	0.00757	CcSEcCtD
Naloxone—Cardiac disorder—Methotrexate—bone cancer	8.99e-05	0.00756	CcSEcCtD
Naloxone—Sweating—Doxorubicin—bone cancer	8.95e-05	0.00753	CcSEcCtD
Naloxone—CREB1—Axon guidance—MMP9—bone cancer	8.94e-05	0.000411	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—GNA11—bone cancer	8.91e-05	0.00041	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—IL3—bone cancer	8.9e-05	0.000409	CbGpPWpGaD
Naloxone—CREB1—Circadian rythm related genes—TP53—bone cancer	8.89e-05	0.000409	CbGpPWpGaD
Naloxone—Angiopathy—Methotrexate—bone cancer	8.79e-05	0.00739	CcSEcCtD
Naloxone—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	8.76e-05	0.000403	CbGpPWpGaD
Naloxone—Mediastinal disorder—Methotrexate—bone cancer	8.73e-05	0.00734	CcSEcCtD
Naloxone—ESR1—Integrated Breast Cancer Pathway—EGFR—bone cancer	8.72e-05	0.000401	CbGpPWpGaD
Naloxone—Chills—Methotrexate—bone cancer	8.69e-05	0.00731	CcSEcCtD
Naloxone—ESR1—Signaling by ERBB4—EGFR—bone cancer	8.67e-05	0.000399	CbGpPWpGaD
Naloxone—CREB1—Immune System—ATF1—bone cancer	8.66e-05	0.000398	CbGpPWpGaD
Naloxone—Diarrhoea—Cisplatin—bone cancer	8.58e-05	0.00722	CcSEcCtD
Naloxone—ALB—Folate Metabolism—TP53—bone cancer	8.57e-05	0.000394	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—MMP2—bone cancer	8.49e-05	0.00039	CbGpPWpGaD
Naloxone—Mental disorder—Methotrexate—bone cancer	8.48e-05	0.00714	CcSEcCtD
Naloxone—CREB1—Innate Immune System—KIT—bone cancer	8.46e-05	0.000389	CbGpPWpGaD
Naloxone—CREB1—Immune System—IL3—bone cancer	8.44e-05	0.000388	CbGpPWpGaD
Naloxone—Cardiac disorder—Epirubicin—bone cancer	8.41e-05	0.00707	CcSEcCtD
Naloxone—Flushing—Epirubicin—bone cancer	8.41e-05	0.00707	CcSEcCtD
Naloxone—OPRM1—GPCR downstream signaling—GNA11—bone cancer	8.29e-05	0.000381	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—SMO—bone cancer	8.23e-05	0.000379	CbGpPWpGaD
Naloxone—Angiopathy—Epirubicin—bone cancer	8.22e-05	0.00692	CcSEcCtD
Naloxone—OPRK1—Signaling Pathways—GRM1—bone cancer	8.17e-05	0.000376	CbGpPWpGaD
Naloxone—Mediastinal disorder—Epirubicin—bone cancer	8.17e-05	0.00687	CcSEcCtD
Naloxone—Chills—Epirubicin—bone cancer	8.13e-05	0.00684	CcSEcCtD
Naloxone—CREB1—Adaptive Immune System—KIT—bone cancer	8.12e-05	0.000374	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—IL3—bone cancer	8.08e-05	0.000371	CbGpPWpGaD
Naloxone—CREB1—Signaling by NGF—EGFR—bone cancer	7.98e-05	0.000367	CbGpPWpGaD
Naloxone—Vomiting—Cisplatin—bone cancer	7.97e-05	0.00671	CcSEcCtD
Naloxone—OPRM1—Signaling Pathways—RGS1—bone cancer	7.96e-05	0.000366	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—GRM4—bone cancer	7.96e-05	0.000366	CbGpPWpGaD
Naloxone—Mental disorder—Epirubicin—bone cancer	7.94e-05	0.00668	CcSEcCtD
Naloxone—ABCB1—Metabolism—NDUFA12—bone cancer	7.93e-05	0.000365	CbGpPWpGaD
Naloxone—Flushing—Doxorubicin—bone cancer	7.78e-05	0.00655	CcSEcCtD
Naloxone—Cardiac disorder—Doxorubicin—bone cancer	7.78e-05	0.00655	CcSEcCtD
Naloxone—Tension—Epirubicin—bone cancer	7.74e-05	0.00651	CcSEcCtD
Naloxone—ALB—Hemostasis—SPARC—bone cancer	7.68e-05	0.000353	CbGpPWpGaD
Naloxone—Nervousness—Epirubicin—bone cancer	7.66e-05	0.00644	CcSEcCtD
Naloxone—Angiopathy—Doxorubicin—bone cancer	7.61e-05	0.0064	CcSEcCtD
Naloxone—TLR4—Immune System—EGFR—bone cancer	7.6e-05	0.000349	CbGpPWpGaD
Naloxone—Mediastinal disorder—Doxorubicin—bone cancer	7.56e-05	0.00636	CcSEcCtD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	7.54e-05	0.000347	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—NT5C3A—bone cancer	7.54e-05	0.000347	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—GNA11—bone cancer	7.53e-05	0.000346	CbGpPWpGaD
Naloxone—Chills—Doxorubicin—bone cancer	7.52e-05	0.00633	CcSEcCtD
Naloxone—OPRM1—GPCR downstream signaling—IL3—bone cancer	7.52e-05	0.000346	CbGpPWpGaD
Naloxone—ALB—Metabolism—NT5C3A—bone cancer	7.5e-05	0.000345	CbGpPWpGaD
Naloxone—Nausea—Cisplatin—bone cancer	7.45e-05	0.00626	CcSEcCtD
Naloxone—Mental disorder—Doxorubicin—bone cancer	7.35e-05	0.00618	CcSEcCtD
Naloxone—ESR1—Integrated Breast Cancer Pathway—TP53—bone cancer	7.32e-05	0.000336	CbGpPWpGaD
Naloxone—Convulsion—Methotrexate—bone cancer	7.3e-05	0.00614	CcSEcCtD
Naloxone—Agitation—Epirubicin—bone cancer	7.25e-05	0.0061	CcSEcCtD
Naloxone—CREB1—Axon guidance—EGFR—bone cancer	7.23e-05	0.000332	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	7.22e-05	0.000332	CbGpPWpGaD
Naloxone—Tension—Doxorubicin—bone cancer	7.16e-05	0.00603	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	7.13e-05	0.006	CcSEcCtD
Naloxone—Nervousness—Doxorubicin—bone cancer	7.09e-05	0.00596	CcSEcCtD
Naloxone—ESR1—Signaling Pathways—RGS1—bone cancer	7.06e-05	0.000325	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—GRM4—bone cancer	7.06e-05	0.000325	CbGpPWpGaD
Naloxone—ALB—Hemostasis—GNA11—bone cancer	7.03e-05	0.000323	CbGpPWpGaD
Naloxone—CYP3A4—Biological oxidations—GSTP1—bone cancer	6.97e-05	0.000321	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—EIF2S1—bone cancer	6.95e-05	0.00032	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—GRM1—bone cancer	6.9e-05	0.000317	CbGpPWpGaD
Naloxone—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	6.88e-05	0.000316	CbGpPWpGaD
Naloxone—Convulsion—Epirubicin—bone cancer	6.84e-05	0.00575	CcSEcCtD
Naloxone—OPRM1—Signaling by GPCR—IL3—bone cancer	6.83e-05	0.000314	CbGpPWpGaD
Naloxone—Hypertension—Epirubicin—bone cancer	6.81e-05	0.00573	CcSEcCtD
Naloxone—Nervous system disorder—Methotrexate—bone cancer	6.75e-05	0.00568	CcSEcCtD
Naloxone—SLCO1A2—Metabolism—ENO2—bone cancer	6.72e-05	0.000309	CbGpPWpGaD
Naloxone—Agitation—Doxorubicin—bone cancer	6.71e-05	0.00564	CcSEcCtD
Naloxone—Skin disorder—Methotrexate—bone cancer	6.68e-05	0.00562	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	6.67e-05	0.00561	CcSEcCtD
Naloxone—CREB1—Disease—TGFBR2—bone cancer	6.67e-05	0.000307	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—MDM2—bone cancer	6.66e-05	0.000306	CbGpPWpGaD
Naloxone—Hyperhidrosis—Methotrexate—bone cancer	6.65e-05	0.00559	CcSEcCtD
Naloxone—CREB1—Signaling Pathways—SMO—bone cancer	6.58e-05	0.000303	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—NT5C3A—bone cancer	6.57e-05	0.000302	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—SMO—bone cancer	6.56e-05	0.000302	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—MDM2—bone cancer	6.4e-05	0.000294	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—MMP9—bone cancer	6.38e-05	0.000293	CbGpPWpGaD
Naloxone—ALB—Hemostasis—IL3—bone cancer	6.37e-05	0.000293	CbGpPWpGaD
Naloxone—Convulsion—Doxorubicin—bone cancer	6.32e-05	0.00532	CcSEcCtD
Naloxone—Nervous system disorder—Epirubicin—bone cancer	6.31e-05	0.00531	CcSEcCtD
Naloxone—Hypertension—Doxorubicin—bone cancer	6.3e-05	0.0053	CcSEcCtD
Naloxone—Tachycardia—Epirubicin—bone cancer	6.28e-05	0.00529	CcSEcCtD
Naloxone—Skin disorder—Epirubicin—bone cancer	6.25e-05	0.00526	CcSEcCtD
Naloxone—SLCO1A2—Metabolism—DHFR—bone cancer	6.24e-05	0.000287	CbGpPWpGaD
Naloxone—Hyperhidrosis—Epirubicin—bone cancer	6.22e-05	0.00524	CcSEcCtD
Naloxone—Paraesthesia—Methotrexate—bone cancer	6.18e-05	0.0052	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	6.17e-05	0.00519	CcSEcCtD
Naloxone—Dyspnoea—Methotrexate—bone cancer	6.13e-05	0.00516	CcSEcCtD
Naloxone—ESR1—Signaling Pathways—GRM1—bone cancer	6.12e-05	0.000281	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	6.06e-05	0.000279	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—EZH2—bone cancer	6.04e-05	0.000278	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—GNA11—bone cancer	6.02e-05	0.000277	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—GNA11—bone cancer	6e-05	0.000276	CbGpPWpGaD
Naloxone—Gastrointestinal disorder—Methotrexate—bone cancer	5.94e-05	0.005	CcSEcCtD
Naloxone—Pain—Methotrexate—bone cancer	5.88e-05	0.00495	CcSEcCtD
Naloxone—Nervous system disorder—Doxorubicin—bone cancer	5.84e-05	0.00491	CcSEcCtD
Naloxone—SLCO1A2—Metabolism—GNA11—bone cancer	5.83e-05	0.000268	CbGpPWpGaD
Naloxone—Tachycardia—Doxorubicin—bone cancer	5.81e-05	0.00489	CcSEcCtD
Naloxone—CREB1—Innate Immune System—JUN—bone cancer	5.79e-05	0.000266	CbGpPWpGaD
Naloxone—Skin disorder—Doxorubicin—bone cancer	5.79e-05	0.00487	CcSEcCtD
Naloxone—Paraesthesia—Epirubicin—bone cancer	5.78e-05	0.00486	CcSEcCtD
Naloxone—Hyperhidrosis—Doxorubicin—bone cancer	5.76e-05	0.00484	CcSEcCtD
Naloxone—OPRK1—Signaling Pathways—SMO—bone cancer	5.76e-05	0.000265	CbGpPWpGaD
Naloxone—Dyspnoea—Epirubicin—bone cancer	5.74e-05	0.00483	CcSEcCtD
Naloxone—CREB1—Signaling Pathways—ATF1—bone cancer	5.6e-05	0.000257	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	5.59e-05	0.000257	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—ATF1—bone cancer	5.58e-05	0.000257	CbGpPWpGaD
Naloxone—Gastrointestinal disorder—Epirubicin—bone cancer	5.56e-05	0.00468	CcSEcCtD
Naloxone—Pain—Epirubicin—bone cancer	5.51e-05	0.00463	CcSEcCtD
Naloxone—CREB1—Signaling Pathways—IL3—bone cancer	5.46e-05	0.000251	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IL3—bone cancer	5.44e-05	0.00025	CbGpPWpGaD
Naloxone—Abdominal pain—Methotrexate—bone cancer	5.44e-05	0.00457	CcSEcCtD
Naloxone—Body temperature increased—Methotrexate—bone cancer	5.44e-05	0.00457	CcSEcCtD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	5.39e-05	0.000248	CbGpPWpGaD
Naloxone—Paraesthesia—Doxorubicin—bone cancer	5.35e-05	0.0045	CcSEcCtD
Naloxone—Dyspnoea—Doxorubicin—bone cancer	5.31e-05	0.00447	CcSEcCtD
Naloxone—SLCO1A2—Metabolism—CYP3A4—bone cancer	5.29e-05	0.000243	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—GNA11—bone cancer	5.26e-05	0.000242	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	5.26e-05	0.000242	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—EGFR—bone cancer	5.16e-05	0.000237	CbGpPWpGaD
Naloxone—Gastrointestinal disorder—Doxorubicin—bone cancer	5.14e-05	0.00433	CcSEcCtD
Naloxone—Pain—Doxorubicin—bone cancer	5.09e-05	0.00429	CcSEcCtD
Naloxone—Abdominal pain—Epirubicin—bone cancer	5.09e-05	0.00428	CcSEcCtD
Naloxone—Body temperature increased—Epirubicin—bone cancer	5.09e-05	0.00428	CcSEcCtD
Naloxone—Asthenia—Methotrexate—bone cancer	4.94e-05	0.00415	CcSEcCtD
Naloxone—CREB1—Immune System—KIT—bone cancer	4.93e-05	0.000227	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—ATF1—bone cancer	4.89e-05	0.000225	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—NDUFA12—bone cancer	4.89e-05	0.000225	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—SMO—bone cancer	4.86e-05	0.000224	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	4.86e-05	0.000223	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IL3—bone cancer	4.77e-05	0.000219	CbGpPWpGaD
Naloxone—Body temperature increased—Doxorubicin—bone cancer	4.71e-05	0.00396	CcSEcCtD
Naloxone—Abdominal pain—Doxorubicin—bone cancer	4.71e-05	0.00396	CcSEcCtD
Naloxone—Diarrhoea—Methotrexate—bone cancer	4.71e-05	0.00396	CcSEcCtD
Naloxone—CREB1—Signaling Pathways—TGFBR2—bone cancer	4.67e-05	0.000215	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TGFBR2—bone cancer	4.65e-05	0.000214	CbGpPWpGaD
Naloxone—Asthenia—Epirubicin—bone cancer	4.62e-05	0.00389	CcSEcCtD
Naloxone—CREB1—Innate Immune System—EGFR—bone cancer	4.55e-05	0.000209	CbGpPWpGaD
Naloxone—CREB1—Disease—KIT—bone cancer	4.55e-05	0.000209	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—GSTP1—bone cancer	4.52e-05	0.000208	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—GNA11—bone cancer	4.45e-05	0.000205	CbGpPWpGaD
Naloxone—Diarrhoea—Epirubicin—bone cancer	4.41e-05	0.00371	CcSEcCtD
Naloxone—CREB1—Signaling Pathways—IGF1R—bone cancer	4.39e-05	0.000202	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IGF1R—bone cancer	4.38e-05	0.000201	CbGpPWpGaD
Naloxone—Vomiting—Methotrexate—bone cancer	4.37e-05	0.00368	CcSEcCtD
Naloxone—CREB1—Adaptive Immune System—EGFR—bone cancer	4.37e-05	0.000201	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—SMO—bone cancer	4.31e-05	0.000198	CbGpPWpGaD
Naloxone—CREB1—Disease—BRAF—bone cancer	4.28e-05	0.000197	CbGpPWpGaD
Naloxone—Asthenia—Doxorubicin—bone cancer	4.27e-05	0.0036	CcSEcCtD
Naloxone—ALB—Hemostasis—PLAU—bone cancer	4.18e-05	0.000192	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—ATF1—bone cancer	4.14e-05	0.00019	CbGpPWpGaD
Naloxone—Vomiting—Epirubicin—bone cancer	4.09e-05	0.00344	CcSEcCtD
Naloxone—Nausea—Methotrexate—bone cancer	4.09e-05	0.00344	CcSEcCtD
Naloxone—OPRK1—Signaling Pathways—TGFBR2—bone cancer	4.08e-05	0.000188	CbGpPWpGaD
Naloxone—Diarrhoea—Doxorubicin—bone cancer	4.08e-05	0.00343	CcSEcCtD
Naloxone—CYP3A4—Metabolism—NT5C3A—bone cancer	4.05e-05	0.000186	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IL3—bone cancer	4.03e-05	0.000185	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—GNA11—bone cancer	3.94e-05	0.000181	CbGpPWpGaD
Naloxone—CREB1—Immune System—MDM2—bone cancer	3.88e-05	0.000178	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IGF1R—bone cancer	3.84e-05	0.000177	CbGpPWpGaD
Naloxone—Nausea—Epirubicin—bone cancer	3.82e-05	0.00322	CcSEcCtD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	3.82e-05	0.000176	CbGpPWpGaD
Naloxone—Vomiting—Doxorubicin—bone cancer	3.79e-05	0.00319	CcSEcCtD
Naloxone—ESR1—Signaling Pathways—ATF1—bone cancer	3.67e-05	0.000169	CbGpPWpGaD
Naloxone—CREB1—Disease—MDM2—bone cancer	3.58e-05	0.000165	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IL3—bone cancer	3.58e-05	0.000164	CbGpPWpGaD
Naloxone—Nausea—Doxorubicin—bone cancer	3.54e-05	0.00298	CcSEcCtD
Naloxone—CREB1—Disease—PTGS2—bone cancer	3.45e-05	0.000159	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TGFBR2—bone cancer	3.45e-05	0.000159	CbGpPWpGaD
Naloxone—CREB1—Immune System—JUN—bone cancer	3.37e-05	0.000155	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ENO2—bone cancer	3.3e-05	0.000152	CbGpPWpGaD
Naloxone—ALB—Metabolism—ENO2—bone cancer	3.29e-05	0.000151	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IGF1R—bone cancer	3.25e-05	0.000149	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	3.21e-05	0.000148	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—KIT—bone cancer	3.19e-05	0.000146	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—KIT—bone cancer	3.18e-05	0.000146	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—DHFR—bone cancer	3.07e-05	0.000141	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TGFBR2—bone cancer	3.06e-05	0.000141	CbGpPWpGaD
Naloxone—ALB—Metabolism—DHFR—bone cancer	3.05e-05	0.00014	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—BRAF—bone cancer	2.99e-05	0.000138	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—BRAF—bone cancer	2.99e-05	0.000137	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—EGFR—bone cancer	2.9e-05	0.000133	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—EGFR—bone cancer	2.89e-05	0.000133	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ENO2—bone cancer	2.88e-05	0.000132	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IGF1R—bone cancer	2.88e-05	0.000132	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GNA11—bone cancer	2.86e-05	0.000132	CbGpPWpGaD
Naloxone—ALB—Metabolism—GNA11—bone cancer	2.85e-05	0.000131	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—KIT—bone cancer	2.78e-05	0.000128	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—DHFR—bone cancer	2.67e-05	0.000123	CbGpPWpGaD
Naloxone—CREB1—Immune System—EGFR—bone cancer	2.65e-05	0.000122	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—BRAF—bone cancer	2.62e-05	0.00012	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CYP3A4—bone cancer	2.6e-05	0.000119	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.58e-05	0.000119	CbGpPWpGaD
Naloxone—ALB—Metabolism—CYP3A4—bone cancer	2.58e-05	0.000119	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.57e-05	0.000118	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—EGFR—bone cancer	2.54e-05	0.000117	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MDM2—bone cancer	2.51e-05	0.000115	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MDM2—bone cancer	2.5e-05	0.000115	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GNA11—bone cancer	2.5e-05	0.000115	CbGpPWpGaD
Naloxone—CREB1—Disease—EGFR—bone cancer	2.45e-05	0.000113	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—KIT—bone cancer	2.35e-05	0.000108	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PTGS2—bone cancer	2.34e-05	0.000108	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CYP3A4—bone cancer	2.26e-05	0.000104	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GSTP1—bone cancer	2.22e-05	0.000102	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—BRAF—bone cancer	2.21e-05	0.000102	CbGpPWpGaD
Naloxone—ALB—Metabolism—GSTP1—bone cancer	2.21e-05	0.000102	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MDM2—bone cancer	2.19e-05	0.000101	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—JUN—bone cancer	2.18e-05	0.0001	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—JUN—bone cancer	2.17e-05	0.0001	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—EGFR—bone cancer	2.14e-05	9.86e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MMP9—bone cancer	2.12e-05	9.76e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MMP9—bone cancer	2.12e-05	9.72e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—KIT—bone cancer	2.09e-05	9.59e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—BRAF—bone cancer	1.96e-05	9.02e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GSTP1—bone cancer	1.94e-05	8.9e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—JUN—bone cancer	1.91e-05	8.76e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MMP9—bone cancer	1.85e-05	8.53e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MDM2—bone cancer	1.85e-05	8.52e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ENO2—bone cancer	1.77e-05	8.15e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—EGFR—bone cancer	1.71e-05	7.88e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—EGFR—bone cancer	1.71e-05	7.86e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—TP53—bone cancer	1.68e-05	7.72e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—DHFR—bone cancer	1.65e-05	7.56e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MDM2—bone cancer	1.64e-05	7.56e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—JUN—bone cancer	1.61e-05	7.41e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MMP9—bone cancer	1.57e-05	7.21e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GNA11—bone cancer	1.54e-05	7.07e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—EGFR—bone cancer	1.5e-05	6.89e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—TP53—bone cancer	1.44e-05	6.62e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TP53—bone cancer	1.44e-05	6.6e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—JUN—bone cancer	1.43e-05	6.57e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MMP9—bone cancer	1.39e-05	6.39e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—EGFR—bone cancer	1.27e-05	5.82e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TP53—bone cancer	1.26e-05	5.79e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GSTP1—bone cancer	1.19e-05	5.48e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PTGS2—bone cancer	1.15e-05	5.29e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PTGS2—bone cancer	1.14e-05	5.26e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—EGFR—bone cancer	1.12e-05	5.16e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TP53—bone cancer	1.06e-05	4.89e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PTGS2—bone cancer	1e-05	4.61e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TP53—bone cancer	9.43e-06	4.34e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PTGS2—bone cancer	6.18e-06	2.84e-05	CbGpPWpGaD
